Pain Management in Glioblastoma Patients

Introduction to Pain Management

A multimodal approach using opioid analgesics combined with co-analgesics such as anticonvulsants and antidepressants is recommended for headache pain secondary to glioblastoma, following the WHO pain ladder from non-opioids to strong opioids based on pain severity 1
The World Health Organization recommends starting with acetaminophen (paracetamol) 500-1000 mg every 4-6 hours (maximum 4-6g daily) for pain management in glioblastoma patients 1

Consider NSAIDs if no contraindications, such as ibuprofen 400-800 mg every 6 hours (maximum 2.4g daily), naproxen 250-500 mg every 4-6 hours (maximum 2.5g daily), or diclofenac (topical or oral formulations) for glioblastoma-related headache 1
If pain persists despite non-opioid analgesics, consider tramadol 50-100 mg every 4-6 hours (maximum 400 mg daily) or dihydrocodeine 60-120 mg modified release tablets (maximum 240 mg daily) 1

For moderate to severe pain unresponsive to previous steps, consider morphine sulfate oral starting dose 20-40 mg daily (no upper limit, titrate as needed), oxycodone oral starting dose 20 mg daily, or fentanyl transdermal starting dose 25 μg/h 1
The National Comprehensive Cancer Network recommends gabapentin starting 100-300 mg nightly, increasing to 900-3600 mg daily in divided doses, or pregabalin starting 50 mg three times daily, increasing to 100 mg three times daily (maximum 600 mg daily) for neuropathic pain management in glioblastoma patients 2

Consider tricyclic antidepressants, such as nortriptyline or desipramine, starting 10-25 mg nightly, increasing to 50-150 mg nightly, for neuropathic pain management in glioblastoma patients 2
Other options include duloxetine starting 30-60 mg daily, increasing to 60-120 mg daily, or venlafaxine starting 50-75 mg daily, increasing to 75-225 mg daily 2

Consider lidocaine patch 5% applied daily to the painful site, or diclofenac gel applied three times daily, for localized pain management in glioblastoma patients 2

Consider dexamethasone for reducing peritumoral edema, which may alleviate headache symptoms, but monitor for adverse effects including insomnia, mood changes, hyperglycemia, and gastric irritation 1

Prescribe short-acting opioid formulations for breakthrough pain, and if more than four breakthrough doses are needed daily, increase the baseline opioid treatment 1

Acknowledge emotional reactions to pain as normal, provide clear information about the pain management plan, express commitment to ongoing pain management, and emphasize that additional options are always available if initial treatments fail 2

Undertreatment of pain due to fear of opioid side effects, failure to address the neuropathic component of pain with appropriate co-analgesics, overreliance on NSAIDs, and inadequate management of medication side effects can lead to poor pain control in glioblastoma patients 1
Administer tramadol with caution, using a recommended dose of 50-100 mg every 4-6 hours, and consider a slower infusion rate of 15-21 drops/minute over 3-4 hours to minimize adverse effects such as nausea and dizziness 1
Monitor patients for nausea, dizziness, and sedation during tramadol administration, and consider prophylactic antiemetics for patients with a history of opioid-induced nausea 1